Project Grant R43TR006332
Award Date 8/15/26
Completion Date 8/14/27
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Denver, CO 80207, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,918 to Cascade Biocatalysts Inc. will fund research and development to demonstrate the commercial feasibility and scalability of a patent-pending approach for stabilizing enzymes through engineered polymer-enzyme interactions. The goal is to enable environmentally sustainable, low-carbon chemical manufacturing processes that utilize enzymes as catalysts, which can decrease...
- The National Center for Advancing Translational Sciences awarded Intero Biosystems Inc. $1.046897 million in project grant funding on July 1, 2026, under CFDA 93.350. Intero Biosystems will develop a stem cell-derived human intestinal organoid platform for drug discovery and preclinical testing. The platform incorporates multiple cell types of the native intestine to model both normal intestinal function and disease processes. Phase II work will scale production methods and validate assay...
- The National Center for Advancing Translational Sciences, National Institutes of Health awarded Zaiput Flow Technologies LLC $306,301 on August 15, 2026, under the NCATS program (CFDA 93.350) to develop a continuous, scalable, safe hydrogenation solution for pharmaceutical manufacturing. Zaiput will design and test an advanced gas-liquid distribution module and demonstrate scalable reaction results in Phase I. The work combines Zaiput's layered modular reactor design with W.L. Gore's advanced...
- The National Center for Advancing Translational Sciences awarded CFD Research Corporation $349,752 on August 17, 2026, under NCATS' translational science grant program (CFDA 93.350, NCATS program). The award funds development of the High-Throughput Organoid Platform for Electrophysiology Studies (HOPES)—an integrated, automated system for growing, maintaining, and screening brain organoids at high throughput using multi-electrode array (MEA) technology embedded in a microphysiological system...
- This $228,697 National Science Foundation award under the Engineering program (CFDA 47.041) will support the development of an optical biosensor technology to facilitate drug screening and validation efforts. Auctus Biologics, Inc. will utilize a proprietary temperature, pH, and chemically stable protein composed of two fragments that bind with antibody-like affinity and specificity. Over the one-year period ending January 2023, the company will establish the technology's suitability for...
- The National Science Foundation awarded a $5.521 million cooperative agreement to Caravel Bio, Inc. on October 1, 2025, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop protein engineering and cell-free biosynthesis technologies. The work integrates computational protein design, bacterial spore display for high-throughput screening, incorporation of non-standard amino acids, and machine learning optimization to establish a universal workflow for protein...
- The National Center for Advancing Translational Sciences at the National Institutes of Health awarded $931,463 to Acousticabio, Inc. on August 1, 2026, under SBIR Phase II funding (CFDA 93.350) to develop microgel-based formulations enabling subcutaneous delivery of monoclonal antibodies at ultra-high concentrations. Monoclonal antibodies currently require intravenous administration because their structural complexity and poor stability make high-concentration formulation difficult. IV...
- The National Institutes of Health Office of the Director awarded the University of California Santa Cruz $714,870 on September 4, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop bifunctional small molecules for biosensing and continuous enzyme evolution. The project addresses two bottlenecks in directed enzyme evolution: the low throughput of classical analytical methods, which explore only 10² variants per round, and the labor-intensive manual operations between...
- The National Center for Advancing Translational Sciences awarded Goeppert LLC, a Philadelphia-based small disadvantaged business, $350,000 on July 1, 2026, under CFDA 93.350 (National Center for Advancing Translational Sciences) to develop NANO-PAVE, a nanopore-based platform for assessing adeno-associated virus (AAV) capsid quality in gene therapy manufacturing. NANO-PAVE addresses a critical bottleneck in AAV clinical translation: current quality-control assays (ELISA, ddPCR, analytical...
- The National Science Foundation Division of Molecular and Cellular Biosciences awarded The Regents of the University of Colorado $1,058,870 on July 1, 2026, under the Biological Sciences program (CFDA 47.074) to investigate the evolution of novel metabolic pathways from promiscuous enzyme activities. The research uses adaptive laboratory evolution coupled with genetic, omics, and biochemical approaches to understand how individual mutations assemble and optimize novel pathways and how...